Source:http://linkedlifedata.com/resource/pubmed/id/16041541
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0007600,
umls-concept:C0017262,
umls-concept:C0030705,
umls-concept:C0086418,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0254610,
umls-concept:C0524910,
umls-concept:C0936012,
umls-concept:C1149404,
umls-concept:C1515655,
umls-concept:C1518174,
umls-concept:C1533691,
umls-concept:C2239176,
umls-concept:C2911684
|
pubmed:issue |
4
|
pubmed:dateCreated |
2006-1-11
|
pubmed:abstractText |
Type I interferon (IFN) possesses antiviral and antitumor activities and also having an immune regulatory effect, activating cellular immune response and upregulating several cytokines. Recent study has shown that type I IFN upregurates the dendritic cell production of IL-15 capable of activating natural killer cells and CD8+ memory T lymphocytes. However, it is still unknown if type I IFN induces IL-15 production in non-immune cells and if type I IFN affects IL-15 production in vivo. The present study investigated the effect of type I IFNs on IL-15 expression in hepatocellular carcinoma (HCC) cell lines in vitro and in patients with chronic hepatitis C in vivo. When three HCC cell lines, Huh7, HepG2, and JHH4 were cultured in vitro, IFN upregulation of IL-15 expression was observed at both the mRNA and protein levels. In experiments using Huh7 cells, upregulation of IL-15 expression occurred within 24 h of the start of IFN stimulation, and both IFN-alpha and -beta dose-dependently increased IL-15 production in the range from 100 U/ml to 10,000 U/ml of concentration. IFN-beta showed stronger activity in IL-15 production induction in vitro than IFN-alpha. For in vivo examination, sera were obtained from 21 chronic hepatitis C patients treated with IFN and 29 healthy individuals, and the serum IL-15 level was quantified by ELISA. The serum IL-15 level of chronic hepatitis C patients before IFN treatment was similar to that of the healthy controls and significantly increased only during the IFN administration period. These results confirm that IFN-alpha/beta induce IL-15 production and also suggest that IL-15 may be associated with type I IFN-induced immune response.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0340-7004
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
394-403
|
pubmed:meshHeading |
pubmed-meshheading:16041541-Adult,
pubmed-meshheading:16041541-Aged,
pubmed-meshheading:16041541-Antiviral Agents,
pubmed-meshheading:16041541-Carcinoma, Hepatocellular,
pubmed-meshheading:16041541-Female,
pubmed-meshheading:16041541-Hepatitis C, Chronic,
pubmed-meshheading:16041541-Humans,
pubmed-meshheading:16041541-Interferon-alpha,
pubmed-meshheading:16041541-Interferon-beta,
pubmed-meshheading:16041541-Interleukin-15,
pubmed-meshheading:16041541-Liver Neoplasms,
pubmed-meshheading:16041541-Male,
pubmed-meshheading:16041541-Middle Aged,
pubmed-meshheading:16041541-Up-Regulation
|
pubmed:year |
2006
|
pubmed:articleTitle |
Interferon-alpha/beta upregulate IL-15 expression in vitro and in vivo: analysis in human hepatocellular carcinoma cell lines and in chronic hepatitis C patients during interferon-alpha/beta treatment.
|
pubmed:affiliation |
Department of General Medicine, Kyushu University Hospital, 3-3-1, Maidashi Higashiku, Fukuoka, 812-8582, Japan. kyamaji@genmedpr.med.kyushu-u.ac.jp
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|